Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm

globenewswire.com
SKYE The article mentions a class action lawsuit filed against Skye Bioscience, but provides no specific details about the allegations or their impact on the company's business or stock. PRGO Perrigo faces a class action lawsuit alleging failure to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, leading to overstated financial results and a substantial stock price drop after disappointing Q3 2025 results and a slashed fiscal year outlook.

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (NASDAQ:SKYE) and Perrigo Company plc (NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Skye Bioscience, Inc. (NASDAQ:SKYE)

Perrigo Company plc (NYSE:PRGO)

Class Period: February 27, 2023 to November 4, 2025

Lead Plaintiff Deadline: January 16, 2026

According to the complaint, during the class period, defendants failed to disclose: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company's outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company's infant formula business; and (4) that, as a result of the foregoing, the Company's financial results, including earnings and cash flow, were overstated.

Plaintiff alleges that on November 5, 2025, Perrigo announced disappointing financial results for the third quarter ended September 27, 2025. The press release revealed that Perrigo had slashed its fiscal year 2025 outlook "due primarily to infant formula industry dynamics." The same day, Perrigo issued a press release, announcing the Company "is initiating a strategic review of its infant formula business." The press release revealed Perrigo is "reassessing the Company's previously announced investment in this business of $240 million" and that the infant formula business had become "less strategic." On this news, Perrigo's stock price fell $5.09, or 25.2%, to close at $15.10 per share on November 5, 2025.

For more information on the Perrigo class action go to: https://bespc.com/cases/PRGO

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,

derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com